BR112020010989A2 - sistemas de distribuição de droga à base de maitansinoide - Google Patents
sistemas de distribuição de droga à base de maitansinoide Download PDFInfo
- Publication number
- BR112020010989A2 BR112020010989A2 BR112020010989-4A BR112020010989A BR112020010989A2 BR 112020010989 A2 BR112020010989 A2 BR 112020010989A2 BR 112020010989 A BR112020010989 A BR 112020010989A BR 112020010989 A2 BR112020010989 A2 BR 112020010989A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- fact
- compound
- alkyl
- group
- Prior art date
Links
- DFQNUNMOOMTKEA-ZOZFOXAFSA-N C[C@@H]([C@@H]1O[C@@]1(C)[C@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)OC(CN(C)c(cc3)ccc3/C(/C)=N/NC(c(c(S(O)(=O)=O)c3)ccc3NC(CCCCCN(C(C=C3)=O)C3=O)=O)=O)=O)[C@H]1OC2=O Chemical compound C[C@@H]([C@@H]1O[C@@]1(C)[C@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)OC(CN(C)c(cc3)ccc3/C(/C)=N/NC(c(c(S(O)(=O)=O)c3)ccc3NC(CCCCCN(C(C=C3)=O)C3=O)=O)=O)=O)[C@H]1OC2=O DFQNUNMOOMTKEA-ZOZFOXAFSA-N 0.000 description 1
- YSCSMZVCOXYZIY-ZEWQSWIFSA-N C[C@@H]([C@@H]1O[C@@]1(C)[C@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)OC(CSc(cc3)c(C)cc3/C(/C)=N/NC(c(c(S(O)(=O)=O)c3)ccc3NC(CCCCCN(CC=C3)C3=O)=O)=O)=O)[C@H]1OC2=O Chemical compound C[C@@H]([C@@H]1O[C@@]1(C)[C@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)OC(CSc(cc3)c(C)cc3/C(/C)=N/NC(c(c(S(O)(=O)=O)c3)ccc3NC(CCCCCN(CC=C3)C3=O)=O)=O)=O)[C@H]1OC2=O YSCSMZVCOXYZIY-ZEWQSWIFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593184P | 2017-11-30 | 2017-11-30 | |
| US62/593,184 | 2017-11-30 | ||
| PCT/US2018/063380 WO2019108975A1 (en) | 2017-11-30 | 2018-11-30 | Maytansinoid-based drug delivery systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020010989A2 true BR112020010989A2 (pt) | 2020-11-17 |
Family
ID=64744962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020010989-4A BR112020010989A2 (pt) | 2017-11-30 | 2018-11-30 | sistemas de distribuição de droga à base de maitansinoide |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11572373B2 (https=) |
| EP (1) | EP3717018A1 (https=) |
| JP (2) | JP7442821B2 (https=) |
| KR (1) | KR20200117988A (https=) |
| CN (1) | CN111712263B (https=) |
| AU (1) | AU2018375788A1 (https=) |
| BR (1) | BR112020010989A2 (https=) |
| CA (1) | CA3083985A1 (https=) |
| IL (2) | IL274920B2 (https=) |
| MX (1) | MX2020005472A (https=) |
| WO (1) | WO2019108975A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6948708B2 (ja) | 2015-06-19 | 2021-10-13 | センチュリオン バイオファーマ コーポレイション | 薬物制御放出のための送達系 |
| EP4344747A3 (en) | 2017-11-30 | 2024-07-03 | LadRx Corporation | Albumin-binding prodrugs of auristatin e derivatives |
| CN110227164B (zh) | 2018-03-06 | 2021-11-23 | 江苏吉贝尔药业股份有限公司 | 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用 |
| JP2024546948A (ja) | 2021-12-15 | 2024-12-26 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | コンジュゲート、それらの組成物、及びそれらの関連する方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125704A (en) | 1977-09-14 | 1978-11-14 | Sri International | Phenyl-substituted rubidazone analogs |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US4966999A (en) | 1988-06-07 | 1990-10-30 | Cytogen Corporation | Radiohalogenated compounds for site specific labeling |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| NZ547370A (en) | 2003-12-04 | 2010-09-30 | Amr Technology Inc | Vinca derivatives |
| CN101743020A (zh) | 2007-05-16 | 2010-06-16 | Ktb肿瘤研究有限责任公司 | 低粘度蒽环制剂 |
| EP2289558A1 (en) | 2009-08-25 | 2011-03-02 | KTB Tumorforschungsgesellschaft mbH | Bisphosphonate-prodrugs |
| WO2012145112A2 (en) * | 2011-04-18 | 2012-10-26 | Immunogen, Inc. | Novel maytansinoid derivatives with sulfoxide linker |
| CN104185477B (zh) | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
| EP2630971B8 (en) | 2012-02-21 | 2017-12-13 | Vergell Medical S.A. | Combinations of albumin-based drug delivery systems |
| CA2891280C (en) * | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| CN104688740A (zh) | 2012-12-21 | 2015-06-10 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| US20140221429A1 (en) | 2013-02-04 | 2014-08-07 | Saud Ibrahim Al-Resayes | Heterocyclic schiff's bases as novel and new antiglycation agents |
| EP3566750A3 (en) * | 2013-02-28 | 2020-04-08 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| BR112017020149A8 (pt) * | 2015-03-27 | 2023-05-02 | Regeneron Pharma | Derivados de maitansinoide, conjugados dos mesmos e métodos de uso |
| WO2016205378A1 (en) | 2015-06-15 | 2016-12-22 | Abbott Diabetes Care Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
| JP6948708B2 (ja) * | 2015-06-19 | 2021-10-13 | センチュリオン バイオファーマ コーポレイション | 薬物制御放出のための送達系 |
| EP4344747A3 (en) | 2017-11-30 | 2024-07-03 | LadRx Corporation | Albumin-binding prodrugs of auristatin e derivatives |
-
2018
- 2018-11-30 AU AU2018375788A patent/AU2018375788A1/en not_active Abandoned
- 2018-11-30 IL IL274920A patent/IL274920B2/en unknown
- 2018-11-30 IL IL305268A patent/IL305268A/en unknown
- 2018-11-30 MX MX2020005472A patent/MX2020005472A/es unknown
- 2018-11-30 JP JP2020529491A patent/JP7442821B2/ja active Active
- 2018-11-30 US US16/768,418 patent/US11572373B2/en active Active
- 2018-11-30 BR BR112020010989-4A patent/BR112020010989A2/pt not_active Application Discontinuation
- 2018-11-30 CN CN201880088076.0A patent/CN111712263B/zh active Active
- 2018-11-30 CA CA3083985A patent/CA3083985A1/en active Pending
- 2018-11-30 KR KR1020207018379A patent/KR20200117988A/ko not_active Ceased
- 2018-11-30 EP EP18822213.7A patent/EP3717018A1/en active Pending
- 2018-11-30 WO PCT/US2018/063380 patent/WO2019108975A1/en not_active Ceased
-
2022
- 2022-12-21 US US18/086,076 patent/US20230391794A1/en not_active Abandoned
-
2023
- 2023-09-19 JP JP2023151472A patent/JP2023164604A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3717018A1 (en) | 2020-10-07 |
| IL274920B1 (en) | 2023-09-01 |
| US20200385403A1 (en) | 2020-12-10 |
| RU2020121456A (ru) | 2021-12-30 |
| CN111712263A (zh) | 2020-09-25 |
| AU2018375788A1 (en) | 2020-07-09 |
| JP2021505551A (ja) | 2021-02-18 |
| JP7442821B2 (ja) | 2024-03-05 |
| CA3083985A1 (en) | 2019-06-06 |
| WO2019108975A1 (en) | 2019-06-06 |
| US11572373B2 (en) | 2023-02-07 |
| CN111712263B (zh) | 2024-12-17 |
| JP2023164604A (ja) | 2023-11-10 |
| IL274920A (en) | 2020-07-30 |
| US20230391794A1 (en) | 2023-12-07 |
| MX2020005472A (es) | 2020-11-11 |
| KR20200117988A (ko) | 2020-10-14 |
| IL274920B2 (en) | 2024-01-01 |
| RU2020121456A3 (https=) | 2022-04-13 |
| IL305268A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11377473B2 (en) | Albumin-binding prodrugs of auristatin E derivatives | |
| US20230391794A1 (en) | Maytansinoid-based drug delivery systems | |
| AU2016279051B2 (en) | Delivery systems for controlled drug release | |
| AU2023340311A1 (en) | Linker for antibody-drug conjugate and use thereof | |
| RU2783076C2 (ru) | Системы доставки лекарств на основе майтанзиноида | |
| RU2795101C2 (ru) | Альбумин-связывающие пролекарства на основе производных ауристатина е | |
| CA3083983C (en) | Albumin-binding prodrugs of auristatin e derivatives | |
| HK40110772A (en) | Albumin-binding prodrugs of auristatin e derivatives | |
| HK40040808A (en) | Albumin-binding prodrugs of auristatin e derivatives | |
| HK40040808B (en) | Albumin-binding prodrugs of auristatin e derivatives | |
| HK40069235A (en) | Delivery systems for controlled drug release | |
| BR112017027445B1 (pt) | Compostos, composição farmacêutica e uso dos mesmos para tratar um câncer, uma doença viral, uma doença autoimune, uma doença inflamatória aguda ou crônica e uma doença causada por bactérias, fungos, ou outros micro-organismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: CYTRX CORPORATION (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: LADRX CORPORATION (US) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |